Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 20.45% is 187% above its 5-year average of 7.11%, near the high end of its 5-year range (-68.71%–27.42%).
631.40% above its 12-month average of 2.80%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 15.96%.
NET PROFIT MARGIN
20.45%
NET PROFIT MARGIN AVG TTM
2.80%
NET PROFIT MARGIN AVG 3Y
15.53%
NET PROFIT MARGIN AVG 5Y
7.11%
NET PROFIT MARGIN AVG 10Y
15.11%
NET PROFIT MARGIN AVG 15Y
18.41%
NET PROFIT MARGIN AVG 20Y
16.31%
CURRENT VS TTM AVG
+631.40%
CURRENT VS 3Y AVG
+31.71%
CURRENT VS 5Y AVG
+187.47%
CURRENT VS 10Y AVG
+35.34%
CURRENT VS 15Y AVG
+11.08%
CURRENT VS 20Y AVG
+25.38%
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+5942.86%
vs the sector median at left
Jazz Pharmaceuticals plc
Market Cap
$14.54B
Net Profit Margin
20.45%
TTM Avg
2.80%
3Y Avg
15.53%
5Y Avg
7.11%
Market Cap
$14.63B
Net Profit Margin
20.91%
TTM Avg
15.61%
3Y Avg
13.71%
5Y Avg
16.95%
Market Cap
$14.66B
Net Profit Margin
35.33%
TTM Avg
28.88%
3Y Avg
23.04%
5Y Avg
19.31%
Market Cap
$14.69B
Net Profit Margin
-5.96%
TTM Avg
-1.67%
3Y Avg
5.09%
5Y Avg
7.31%
Market Cap
$14.04B
Net Profit Margin
71.08%
TTM Avg
-67.82%
3Y Avg
-363.95%
5Y Avg
-2068.81%
Market Cap
$15.07B
Net Profit Margin
17.26%
TTM Avg
12.25%
3Y Avg
14.36%
5Y Avg
15.15%
Market Cap
$13.81B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2793.69%
5Y Avg
-3700.03%
Market Cap
$13.11B
Net Profit Margin
-97.64%
TTM Avg
-193.35%
3Y Avg
-1980.08%
5Y Avg
-2361.16%
Market Cap
$13.01B
Net Profit Margin
24.86%
TTM Avg
33.22%
3Y Avg
32.75%
5Y Avg
45.02%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | $14.54B | 20.45% | 2.80% | 15.53% | 7.11% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 20.91% | 15.61% | 13.71% | 16.95% |
| Exelixis, Inc. (EXEL)vs › | $14.66B | 35.33% | 28.88% | 23.04% | 19.31% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | -5.96% | -1.67% | 5.09% | 7.31% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | 71.08% | -67.82% | -363.95% | -2068.81% |
| Solventum Corporation (SOLV)vs › | $15.07B | 17.26% | 12.25% | 14.36% | 15.15% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | 0.00% | 0.00% | -2793.69% | -3700.03% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | -97.64% | -193.35% | -1980.08% | -2361.16% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 24.86% | 33.22% | 32.75% | 45.02% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 6.61% | 16.89% | 20.26% | 23.62% |
Operating Margin
5.3%
Net Profit Margin
20.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 15.96% |
| 2026-03-31 | 27.42% |
| 2025-12-31 | 16.98% |
| 2025-09-30 | 22.33% |
| 2025-06-30 | -68.71% |
| 2025-03-31 | -10.31% |
| 2024-12-31 | 17.56% |
| 2024-09-30 | 20.38% |
| 2024-06-30 | 16.46% |
| 2024-03-31 | -1.62% |
| 2023-12-31 | 9.30% |
| 2023-09-30 | 15.10% |
| 2023-06-30 | 10.91% |
| 2023-03-31 | 7.78% |
| 2022-12-31 | -24.68% |
| 2022-09-30 | -2.09% |
| 2022-06-30 | 3.72% |
| 2022-03-31 | 0.20% |
| 2021-12-31 | -3.94% |
| 2021-09-30 | -6.30% |
| 2021-06-30 | -48.33% |
| 2021-03-31 | 20.05% |
| 2020-12-31 | 20.05% |
| 2020-09-30 | 24.67% |
| 2020-06-30 | 20.41% |
| 2020-03-31 | -29.52% |
| 2019-12-31 | 12.72% |
| 2019-09-30 | 19.02% |
| 2019-06-30 | 49.03% |
| 2019-03-31 | 16.77% |
| 2018-12-31 | 33.47% |
| 2018-09-30 | 31.81% |
| 2018-06-30 | 18.45% |
| 2018-03-31 | 10.34% |
| 2017-12-31 | 53.21% |
| 2017-09-30 | 15.42% |
| 2017-06-30 | 26.78% |
| 2017-03-31 | 23.01% |
| 2016-12-31 | 29.42% |
| 2016-09-30 | 23.29% |
| 2016-06-30 | 29.20% |
| 2016-03-31 | 22.06% |
| 2015-12-31 | 24.28% |
| 2015-09-30 | 25.80% |
| 2015-06-30 | 26.40% |
| 2015-03-31 | 22.86% |
| 2014-12-31 | 24.87% |
| 2014-09-30 | 8.40% |
| 2014-06-30 | 14.99% |
| 2014-03-31 | -37.52% |
| 2013-12-31 | 23.45% |
| 2013-09-30 | 32.48% |
| 2013-06-30 | 20.26% |
| 2013-03-31 | 22.13% |
| 2012-12-31 | 109.17% |
| 2012-09-30 | 18.92% |
| 2012-06-30 | 20.96% |
| 2012-03-31 | 25.53% |
| 2011-12-31 | 44.86% |
| 2011-09-30 | 44.32% |
| 2011-06-30 | 51.42% |
| 2011-03-31 | 42.90% |
| 2010-12-31 | 45.83% |
| 2010-09-30 | 29.59% |
| 2010-06-30 | -15.78% |
| 2010-03-31 | 4.16% |
| 2009-12-31 | 14.77% |
| 2009-09-30 | -5.43% |
| 2009-06-30 | 5.82% |
| 2009-03-31 | -58.83% |
| 2008-12-31 | -290.58% |
| 2008-09-30 | -162.34% |
| 2008-06-30 | -333.87% |
| 2008-03-31 | -319.19% |
| 2007-12-31 | -387.80% |
| 2007-09-30 | -90.15% |
| 2007-06-30 | -279.47% |
| 2007-03-31 | -139.01% |
| 2006-12-31 | -105.69% |
| 2006-09-30 | -105.69% |
| 2006-06-30 | -105.69% |
| 2006-03-31 | -227.50% |
| 2005-12-31 | -397.18% |
| 2005-09-30 | -397.11% |
| 2005-06-30 | -397.11% |
| 2005-03-31 | -397.11% |
